Pancreatic Neuroendocrine Tumor Clinical Trial
Official title:
A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
The purpose of this research study is to determine the effectiveness of AMG 479 against carcinoid and pancreatic neuroendocrine tumors. AMG 479 is an antibody that is made in the laboratory. Antibodies are highly specific proteins produced by the body's immune system that recognize foreign substances in the body. AMG 479 has been used in other research studies and information from those other research studies suggests that AMG 479 may help to prevent the growth of some neuroendocrine tumors. The observed antitumor activity of AMG 479, together with the current limited treatment options available for patients with neuroendocrine tumors, warrant further investigation of AMG 479 in this patient population.
Neuroendocrine tumors (NETs) comprise a heterogeneous spectrum of neoplasms. NETs are commonly subclassified into two broad subgroups according to their site of origin: pancreatic NETs are thought to arise from the endocrine cells of the pancreas, whereas NETs of other sites such as the lungs or gastrointestinal tract are often referred to as carcinoid tumors. While histologically similar, carcinoid tumors and pancreatic neuroendocrine tumors have demonstrated different response rates in prior phase II studies of antitumor agents. Because of these differences, we will perform the current study using two cohorts of patients (30 with carcinoid and 30 with pancreatic neuroendocrine tumors). The statistical design, however, is the same for both cohorts. With 30 patients in each cohort, this study has 80% power assuming type I error of 6% to differentiate a >/=17% objective response rate from a </=5% objective response rate using a single stage design. The proposed regimen would be promising in either cohort if at least 4 of 30 patients achieve an objective response. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05566093 -
EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors
|
N/A | |
Completed |
NCT00970970 -
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
|
||
Recruiting |
NCT05568017 -
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
|
Phase 2 | |
Not yet recruiting |
NCT06024343 -
Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction
|
N/A | |
Recruiting |
NCT03891784 -
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT03204019 -
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
|
Phase 2 | |
Completed |
NCT00804336 -
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
|
Phase 1 | |
Recruiting |
NCT05997056 -
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
|
Phase 2 | |
Not yet recruiting |
NCT06158516 -
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05040360 -
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00576680 -
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05610826 -
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03074513 -
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
|
Phase 2 | |
Completed |
NCT03967951 -
CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
|
||
Not yet recruiting |
NCT03435770 -
Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms
|
N/A | |
Recruiting |
NCT04134832 -
Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
|
||
Recruiting |
NCT05554744 -
EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors
|
N/A | |
Completed |
NCT02159989 -
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Not yet recruiting |
NCT06406387 -
ATRX/DAXX in EUS-FNB Specimens of Pan-NETs
|